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Abstract
Background: To compare the effect of aprotinin with the effect of lysine analogues (tranexamic acid and e-aminocaproic
acid) on early mortality in three subgroups of patients: low, intermediate and high risk of cardiac surgery.
Methods and Findings: We performed a meta-analysis of randomised controlled trials and observational with the following
data sources: Medline, Cochrane Library, and reference lists of identified articles. The primary outcome measure was early
(in-hospital/30-day) mortality. The secondary outcome measures were any transfusion of packed red blood cells within
24 hours after surgery, any re-operation for bleeding or massive bleeding, and acute renal dysfunction or failure within the
selected cited publications, respectively. Out of 328 search results, 31 studies (15 trials and 16 observational studies)
included 33,501 patients. Early mortality was significantly increased after aprotinin vs. lysine analogues with a pooled risk
ratio (95% CI) of 1.58 (1.13–2.21), p,0.001 in the low (n=14,297) and in the intermediate risk subgroup (1.42 (1.09–1.84),
p,0.001; n=14,427), respectively. Contrarily, in the subgroup of high risk patients (n=4,777), the risk for mortality did not
differ significantly between aprotinin and lysine analogues (1.03 (0.67–1.58), p=0.90).
Conclusion: Aprotinin may be associated with an increased risk of mortality in low and intermediate risk cardiac surgery, but
presumably may has no effect on early mortality in a subgroup of high risk cardiac surgery compared to lysine analogues.
Thus, decisions to re-license aprotinin in lower risk patients should critically be debated. In contrast, aprotinin might
probably be beneficial in high risk cardiac surgery as it reduces risk of transfusion and bleeding complications.
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Introduction
Excessive postoperative bleeding after cardiac surgery increases
transfusion requirements, which is associated with postoperative
infections and ischaemic events [1]. A recent systematic review
from the Cochrane Collaboration have demonstrated that
aprotinin is the most effective drug in decreasing perioperative
bleeding and the need for blood transfusion and re-operation [2].
At the end of 2007, however, worldwide marketing of aprotinin
was suspended as the findings from the Blood Conservation using
Antifibrinolytics Trial (BART) suggested a trend towards increased
30-day mortality in the aprotinin treatment arm despite a modest
reduction in the risk of massive bleeding [3]. As a consequence,
use of tranexamic acid and aminocaproic acid increased as
alternative antifibrinolytic agents worldwide, although concerns
are also increasing with regard to potential adverse effects [4].
Moreover, it is unclear if use of lysine analogues is adequate in
patients at highest risk (the originally intended patient population
by Royston et al. [5]) in whom prophylactic treatment with
aprotinin may be of greatest benefit. In this respect, the European
Medicines Agency’s Committee for Medicinal Products for
Human Use (CHMP) revisited its previous recommendation on
aprotinin in February 2012. The CHMP concluded that the
benefits of aprotinin outweigh its risk in appropriately managed
patients undergoing isolated heart bypass surgery (not combined
with other heart surgery), and recommended that the suspension
of aprotinin medicines in the EU should be lifted for this revised
indication.’ [6]
In a retrospective single-center cohort study, Karkouti et al.
previously showed that aprotinin tends to have a better risk-benefit
profile than tranexamic acid in high-risk, but not in low- to
moderate-risk patients [7]. As a meta-analysis of only randomised
PLOS ONE | www.plosone.org 1 March 2013 | Volume 8 | Issue 3 | e58009trials [2] might be too small to provide precise estimates of early
mortality, we performed a more complete assessment of the
epidemiologic evidence and reviewed studies published since 1990,
which have examined the association between aprotinin, tranexa-
mic acid and e-aminocaproic acid regarding early mortality
following cardiac surgery. The study results of the primary
endpoint are reported separately for randomised trials, adjusted
and unadjusted observational studies, respectively.
Methods
Study identification
We undertook a systematic search of the literature to identify
published reports which compared mortality after cardiac surgery
for patients given aprotinin compared with tranexamic acid and e-
aminocaproic acid. We searched Medline using the following
strategy: MeSH terms ‘‘Cardiac Surgical Procedures’’ and
‘‘Humans’’, MeSH Major Topic ‘‘Aprotinin’’ with limits (a)
publication date from 1
st January 1990 to 8
th April 2012, (b)
studies in English, and (c) studies classified as a clinical trial, meta-
analysis, randomised controlled trial, review, clinical trial, phase I,
clinical trial, phase II, clinical trial, phase III, clinical trial, phase
IV, comparative study, controlled clinical trial, corrected and
republished article, evaluation studies, journal article, or multi-
center study. A total of 266 Medline articles were identified and
the abstracts were searched for reference to in-hospital mortality
or mortality to 30-days after surgery. We also searched reference
lists of identified articles and included 12 studies additionally
[8,9,10,11,12,13,14,15,16,17,18,19]. Additionally, we searched
Cochrane Library using ‘‘Cardiac Surgical Procedures’’ and
‘‘Aprotinin’’ with publication date from 1
st January 1990 and
found 50 articles in English. We excluded articles which only
compared aprotinin to control (placebo), duplicates, studies which
did not consider mortality and studies which reported long-term
mortality, studies in children, meta-analyses, comments, case
reports, and reviews (Fig. 1). Again, as a meta-analysis of only
randomised trials (RCT) might be too small to provide precise
estimates of early mortality, we performed a more complete
assessment of the epidemiologic evidence, as it has recently been
performed for other indications if randomized studies are
insufficiently [20]. The study results of the primary endpoint are
reported separately for RCT, adjusted and unadjusted observa-
tional studies. All original studies were abstracted by one reviewer
unblinded to authors, institution and journal. We attempted to
contact the authors of included studies and requested additional
information in terms of mortality if this was not contained in
published articles.
We compared aprotinin versus both lysine analogues (tranexa-
mic acid and/or e-aminocaproic acid) that were not separately
analysed in our review, as the latest Cochrane review by Henry et
al. [2] did not find any significant difference between both
antifibrinolytics in terms of number of exposed allogeneic blood,
re-operation for bleeding, mortality, and other adverse outcome
events (myocardial infarction, stroke, deep vein thrombosis, or
renal failure/dysfunction).
We defined a priori three subgroups of risk for bleeding:
1) Low risk surgery was predominantly defined as isolated
coronary artery bypass graft (CABG) (or single valve surgery),
2) Intermediate risk surgery was predominantly defined as
combined cardiac surgery, e.g. CABG with valve surgery,
3) High risk surgery was predominantly defined as complex
surgery, e.g. redo sternotomy, multiple valve surgery, surgery
of ascending aorta or aortic arch, or emergency surgery.
We also provide a systemic overview of all factors included in
the regression analyses (Table S4 in File S1). Unfortunately, some
studies did not allow allocating the events to a specific type of
surgery. Therefore, the definition of low, intermediate or high risk
surgery was based on the type of surgery that was mainly
performed within the study, although heterogeneity of risk slightly
varied between studies.
Data extraction and quality assessment
All data with regard to authorship, year of publication, study
design (RCT, observational study), study population (sample size,
type of cardiac operation), length of follow-up and clinical
endpoints were extracted. Methodological quality of the included
studies was assessed using the Downs and Black Checklist for both
RCT and observational trials [21]. The Downs and Black tool
comprises six sections that assess reporting (total score: 11),
external validity (total score: 3), internal validity bias (total score:
7), internal validity confounding (total score: 6), and power (total
score: 2). A maximum score of 29 indicates the highest
methodological quality and a score of zero represents the poorest
methodological quality.
Endpoints
The primary endpoint of the systematic review was overall early
mortality. From all studies, we used 30-day mortality. If 30-day
mortality was not reported, we used in-hospital mortality.
Secondary endpoints were i) any transfusion of packed red blood
cells within 24 hours after surgery, ii) any re-operation for bleeding
or massive bleeding, and iii) acute renal dysfunction or failure
within the 31 cited publications, respectively. We used definitions
of acute renal dysfunction or acute renal failure as defined by the
authors in their original papers. The presented studies are selected
to report mortality data.
Statistical analysis
The meta-analysis was done in line with recommendations from
the Preferred Reporting Items for Systemic reviews and Meta-
Analyses (PRISMA statement) [22] and with previous recommen-
dations for reporting observational studies (MOOSE) [23]. In
addition, we reported against the AMSTAR instrument in terms
of the adequacy of conducting this review [24]. All analysis and
graphical illustrations were conducted using R from the R
Foundation for Statistical Computing, Vienna, Austria, particu-
larly the R package meta by G. Schwarzer. Study protocol is
provided in (File S2, File S3).
Risk ratio (RR) and 95% confidence intervals (95% CI) were
calculated using the random effects model (DerSimonian and
Laird estimator) [25]. Typically, studies with larger sample size
received more weight when calculating the RR. RRs are
undefined and excluded for studies with no event in either arm.
For studies with zero events 0.5 is added to the corresponding cells.
The presence of heterogeneity and comparisons of subgroups of
trials was tested by Q-test and the results are given in the figures.
To find a possible evidence for publication bias funnel plots of the
RR were generated and asymmetry was tested by the rank
correlation test based on Kendall’s tau. We considered P,0.05 to
be statistically significant.
Results
A total of 31 published reports (15 trials and 16 observational
studies) were identified. Detailed descriptions of these studies are
given in (Table S1, S2, S3 in File S1). The majority of studies
considered in-hospital mortality (n=21) or mortality to 30-days
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[13]. In terms of studies quality, the median Downs and Black
score was 18.5 (range 12–27 points) considering the total number
of 31 studies.
Meta-analysis of primary endpoint
Analysing 14,297 patients with low risk, aprotinin was
significantly associated with increased early mortality compared
to lysine analogues (1.58 (1.13–2.21), p,0.001). The study results
of the primary endpoint are displayed separately for RCT,
adjusted and unadjusted observational studies in Fig. 2.
In patients with an intermediate risk (n=14,427) risk ratio of
mortality was significantly increased (1.42 (1.09–1.84), p,0.001)
according to the Random effects model (Fig. 3).
In the subgroup of high risk patients (n=4,777), the risk for
mortality did not differ significantly between aprotinin and lysine
analogues (1.03 (0.67–1.58, p=0.90) indicating a probably neutral
effect for aprotinin compared to lysine analogues in terms of early
mortality (Fig. 4).
Funnel plot analysis showed no obvious deviations from
symmetry, so due to this results there are no indications of
publication bias (Kendall’s rank correlation with p.0.20 for all
three risk groups; correlation coefficients: t=0.18 for the low risk
group; t=0.24 for the intermediate risk group; t=20.24 for the
high risk group).
Even so different results are obtained for low, intermediate and
high risk patients, a direct comparison of RR between these three
groups did not reach statistical significance (p=0.11).
Note, that there are also no significant differences between trials
focusing on in-hospital mortality or 30-days mortality (p=0.23)
justifying the combined analysis approach.
Meta-analysis of secondary endpoints (non-representative
sample)
Risk ratio for transfusion of red blood cells within 24 hours after
surgery could be analysed in 18 studies and was 0.84 (0.74–0.96,
p=0.01, n=3,565), 0.90 (0.76–1.05, p=0.19, n=752) and 0.79
(0.70–0.89, p,0.001, n=3,809) in the low, intermediate and high
risk subgroup, respectively (Fig. S1). Risk ratio for re-operation or
any massive bleeding could be analysed in 21 studies and was 0.87
(0.66–1.14, p=0.31, n=5,515), 0.75 (0.09–6.03, p=0.79,
n=752) and 0.79 (0.54–1.14, p=0.20, n=4,776), respectively
(Fig. S2). Out of the 31 selected studies, 15 studies reported data
on either acute renal dysfunction or acute renal failure showing
that risk ratio did not significantly differ between aprotinin and
lysine analogues in the low (1.35 (0.98–1.87), p=0.07, n=4,153),
intermediate (1.10 (0.67–1.83), p=0.70, n=14,058) and high risk
subgroup (1.19 (0.93–1.54), p=0.17, n=4,273), respectively (Fig.
S3).
Discussion
We address a highly topical issue [26,27] – whether aprotinin is
safe to use in certain patient groups?
To best of our knowledge, this is the first review stratifying
cardiac surgical patients to their individual risk for bleeding and
surgical complications, and demonstrating that aprotinin has
diverse effects depending on the risk profile. Specifically, we found
that aprotinin leads to higher mortality in low and intermediate
risk, but presumably may not affect mortality in high risk cardiac
surgical patients.
The suspension of aprotinin a few years ago has forced
clinicians to find alternative blood-sparing agents for use during
cardiac surgery. The two alternatives are the lysine analogues e-
aminocaproic acid which has no approval in Europe or Canada
Figure 1. Flow of information through the different phases of the systemic review.
doi:10.1371/journal.pone.0058009.g001
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exclusively used in these countries. Nevertheless, a few number of
problems with lysine analogues, in particular with tranexamic acid
has emerged, since there is little evidence for a benefit of
tranexamic acid to reduce transfusion burden, particularly in
patients at higher risk for bleeding and transfusion.
Although our meta-analysis mainly focuses on early mortality as
the primary endpoint, we also examined the effects of aprotinin vs.
lysine analogues regarding acute renal dysfunction or failure as a
non-representative sample. This endpoint was reported in 15
studies showing that risk ratio tended to be increased, but did not
significantly differ between aprotinin and lysine analogues in the
low, intermediate and high risk subgroup. Similarly, we recently
found in a retrospective observational study including 9,875
cardiac surgical patients with propensity-adjusted, multivariate
logistic regression [28], that aprotinin did not significantly
increased risk of postoperative renal dysfunction in on-pump
cardiac surgery. Further, the recent Cochrane review [2] including
the ‘head-to-head’ BART study did not find any difference with
any of the antifibrinolytic drugs in terms of kidney failure,
myocardial infarction or stroke.
More interestingly, the recent Cochrane analysis also suggested
beneficial effects of aprotinin by reducing risk of transfusion and
bleeding complications. Moreover, the risk for perioperative use of
blood products such as fresh frozen plasma and cryoprecipitate
may have even increased in the post-aprotinin era [29]. In the
selected studies of our meta-analysis, aprotinin was associated with
a reduced risk for transfusion of red blood cells, and tended to
reduce risk for re-operation or any massive bleeding irrespective of
the surgical risk.
In this respect, the European Medicines Agency recommended
lifting suspension of aprotinin at the 17
th February 2012 as benefits
(less transfusion requirements, less bleeding-associated harm)
outweigh risks (mortality) in restricted range of indications. Very
surprisingly, ‘suspension was lifted in appropriately managed
patients with isolated heart bypass surgery.’ Our present meta-
analysis, however, does not support this recommendation, as
aprotinin was associated with a significant increased risk of early
Figure 2. Early mortality in low risk surgery (subgroup 1). Forrest plot showing risk ratio (95% CI) of studies comparing aprotinin vs. lysine
analogues (tranexamic acid and/or aminocaproic acid, indicated by *) for in-hospital/30-day mortality in a subgroup of low risk cardiac surgical
patients sorted by randomised controlled trials (RCT), adjusted and unadjusted observational studies, respectively.
doi:10.1371/journal.pone.0058009.g002
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patients. Contrarily, aprotinin presumably may not affect mortal-
ity in higher risk surgical patients undergoing complex surgery
who have a higher risk of life threatening haemorrhage and,
consequently, of needing blood transfusion. Aprotinin’s ability to
decrease the risk of transfusion of red blood cells more than
tranexamic acid and aminocaproic acid has repetitively been
proven in most of the studies [2,14,29,30]. The clinical implication
of our findings is that aprotinin may be the antifibrinolytic of
choice and should therefore remain available for clinical use in
these high risk cardiac surgical patients. These are the patients
with multiple co-morbidities who are undergoing emergency, redo
sternotomy, or complex procedures that require prolonged cardio-
pulmonary bypass support, e.g. multiple valve surgery, or surgery
of ascending aorta or aortic arch with hypothermic cardiac arrest.
The propensity matched paired analysis by Karkouti et al. [7]
identified patients whose risk status placed them to the top 10th
percentile of their institution’s cardiac surgery population. These
implications are also supported by a subgroup analysis of the
BART which revealed that aprotinin did not affect early mortality
in elderly patients and patients with high co-morbidity as relative
risk decreased with older age (age,65 years: 3.42 (1.14–10.26) vs.
age.80 years: 0.67 (0.26–1.74)), co-existing morbidity (none: 4.40
(1.28–15.15) vs. co-morbid: 1.24 (0.76–2.03), and higher American
Society of Anesthesiologist (ASA) physical status class (ASA class
,4: 2.18 (0.95–5.04) vs. ASA class $4 points: 1.34 (0.78–2.32)).
This review has also some limitations. First, the definition of
low, intermediate or high risk surgery was based on the type of
surgery that was mainly performed within the respective study,
although the heterogeneity in risk slightly varied between studies.
Unfortunately, some studies did not allow allocating the events to a
specific type of surgery. Secondly, as our present meta-analysis
mainly focussed on early mortality as the primary endpoint,
analysis of secondary endpoints underlay a study selection bias.
Based on the 31 selected studies, the results are descriptive and
non-representative. Data from the latest Cochrane review
including only RCTs [2], however, suggested a significant benefit
of aprotinin over the lysine analogues tranexamic acid and e-
aminocaproic acid in terms of i) reducing perioperative blood loss,
ii) reducing the need for RBC transfusion, and iii) reducing the
need for re-operation due to bleeding, respectively. In addition, a
problem is lack of large prospective randomised studies. We
included 15 RCTs, but even the two largest trials by Casati et al.
[31] and Fergusson et al. [3] that each included more than 1,000
patients did not focus on mortality as the primary endpoint,
respectively. The application of formal meta-analytic methods to
Figure 3. Early mortality in intermediate risk surgery (subgroup 2). Forrest plot showing risk ratio (95% CI) of studies comparing aprotinin vs.
lysine analogues (tranexamic acid and/or aminocaproic acid, indicated by *) for in-hospital/30-day mortality in a subgroup of intermediate risk cardiac
surgical patients sorted by randomised controlled trials (RCT), adjusted and unadjusted observational studies, respectively.
doi:10.1371/journal.pone.0058009.g003
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controversial. One reason for this has been that potential biases
in the original studies make the calculation of a single summary
estimate of effect of exposure potentially misleading [23]. Large
observational studies, which have residual confounding, can
swamp smaller well controlled randomised trials during data
pooling. Nevertheless, we performed a complete assessment of the
epidemiologic evidence, as a meta-analysis of only randomised
trials would be too small to provide precise estimates of early
mortality. Taking into account these methodological limitations,
we reported mortality results separately for RCT, adjusted and
unadjusted observational studies, respectively.
Moreover, the search was limited to published reports in
Medline and Cochrane Library, and the authors did not ask
experts for additional unpublished reports.
Conclusions
First, aprotinin may be associated with increased risk of early
mortality in low and intermediate risk cardiac surgical patients, in
particular in patients with mainly isolated CABG or CABG
combined with valve surgery. Therefore, the recent recommen-
dation of the European Medicines Agency lifting suspension of
aprotinin in lower risk patients should critically be debated.
Secondly, based on the known beneficial effects of aprotinin
reducing risk of transfusion and bleeding complications as well as
the presumably neutral effect on mortality in high risk surgery, our
findings suggest that aprotinin may be warranted in high risk
patients, as determined by their co-morbidities, surgical acuity,
and complexity. Given the observed incidence of mortality and the
strong selection of high risk patients, however, an extremely large
sample size would be required for a prospective randomised trial.
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Figure 4. Early mortality in high risk surgery (subgroup 3). Forrest plot showing risk ratio (95% CI) of studies comparing aprotinin vs. lysine
analogues (tranexamic acid and/or aminocaproic acid, indicated by *) for in-hospital/30-day mortality in a subgroup of high risk cardiac surgical
patients sorted by randomised controlled trials (RCT), adjusted and unadjusted observational studies, respectively.
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within 24 hours after surgery. Forrest plot showing risk ratio
(95% CI) of studies comparing aprotinin vs. lysine analogues
(tranexamic acid and/or aminocaproic acid, indicated by *) for
transfusion of red blood cells within 24 hours after surgery in a
subgroup of low (a), intermediate (b) and high risk (c) cardiac
surgical patients, respectively.
(PDF)
Figure S2 Risk ratio for re-operation or any massive
bleeding. Forrest plot showing risk ratio (95% CI) of studies
comparing aprotinin vs. lysine analogues (tranexamic acid and/or
aminocaproic acid, indicated by *) for re-operation or any massive
bleeding in a subgroup of low (a), intermediate (b) and high risk (c)
cardiac surgical patients, respectively.
(PDF)
Figure S3 Risk ratio for acute renal dysfunction or
acute renal failure. Forrest plot showing risk ratio (95% CI) of
studies comparing aprotinin vs. lysine analogues (tranexamic acid
and/or aminocaproic acid, indicated by *) for acute renal
dysfunction or acute renal failure in a subgroup of low (a),
intermediate (b) and high risk (c) cardiac surgical patients,
respectively. Please note that definition of acute renal dysfunction
and acute renal failure varied moderately between studies.
(PDF)
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